Form 4: Ironwood CCO Sells Shares for Tax Obligations
Insider Transaction Report
Ironwood Pharmaceuticals' Chief Commercial Officer, Tammi L Gaskins, sold 6,016 shares of Class A Common Stock to cover tax withholding obligations related to restricted stock unit vesting.
Summary
- Tammi L Gaskins, Chief Commercial Officer of Ironwood Pharmaceuticals, Inc. (IRWD), reported a sale of Class A Common Stock.
- The transaction involved the disposition of 6,016 shares on November 17, 2025.
- The shares were sold at a price of $3.32 per share.
- The sale was non-discretionary, executed to cover tax withholding obligations associated with the vesting of restricted stock units.
- Following this transaction, Tammi L Gaskins beneficially owns 235,264 shares of Class A Common Stock directly.
Sentiment
Score: 5
Explanation: The filing reports a non-discretionary sale of shares to cover tax obligations, which is a routine event for executives receiving equity compensation and is generally considered neutral in terms of company sentiment.
Future Outlook
This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.
Management Comments
- The sale reported represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units.
- The sale occurred automatically to satisfy the tax withholding obligations to be funded by a sell-to-cover transaction and does not represent a discretionary trade by the Reporting Person.
Industry Context
This Form 4 filing reports a routine insider transaction for tax purposes and does not provide information relevant to broader industry trends or competitive analysis.
Stakeholder Impact
- Shareholders: The sale is a routine, non-discretionary event for tax purposes and is unlikely to have a significant impact on shareholder perception or the company's operational performance.
Key Dates
| Date | Description |
|---|---|
| 11/17/2025 | Date of transaction (sale of Class A Common Stock) |
| 11/19/2025 | Date the Form 4 was signed and filed |
Keywords
Ironwood Pharmaceuticals, IRWD, Form 4, Insider Transaction, Stock Sale, Tax Withholding, Restricted Stock Units, Executive Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.